市场快照
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| CAGR: | 5.36 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
据信，澳大利亚体外诊断市场在预测期内的复合年增长率约为 5.36%。推动市场发展的某些因素是慢性和传染病发病率的增加、老年人口的增长、诊断领域的技术进步以及即时诊断的出现。
- 根据澳大利亚健康与福利研究所 (AIHW) 的数据，2016 年约有 370 万澳大利亚人（占总人口的 15%）年龄在 65 岁及以上。随着老年人口的增加，典型年龄可能会有所增长-相关的健康问题（例如关节炎、痴呆和癌症）。
- 根据 2015 年澳大利亚健康调查 (AHS)，五分之一的老年人 (22%) 报告患有心血管疾病，15% 患有糖尿病，7% 患有癌症。该国慢性病增加的趋势一直在增加；随着慢性病发病率的增加，需要在医疗保健的每个阶段提供关键见解的诊断测试，包括预防、检测、诊断、治疗和健康状况的成功管理。
- 因此，人们认为，不断上升的慢性疾病发病率一直在推动澳大利亚体外诊断市场的发展。
报告范围
根据本报告的范围，体外诊断涉及用于对各种生物样本进行体外测试的医疗设备和消耗品。它们用于诊断各种医疗状况和慢性疾病。
| By Test Type | |
| Clinical Chemistry | |
| Molecular Diagnostics | |
| Immuno Diagnostics | |
| Haematology | |
| Other Test Types |
| By Type of Product | |
| Instruments | |
| Reagents | |
| Other Types of Product |
| By Application | |
| Infectious Disease | |
| Diabetes | |
| Cancer/Oncology | |
| Cardiology | |
| Autoimmune Disease | |
| Other Applications |
| By End User | |
| Diagnostic Laboratories | |
| Hospitals and Clinics | |
| Other End Users |
主要市场趋势
试剂板块预计在预测期内拥有最大的市场份额
所研究的市场试剂部分包括制造商打算在体外诊断过程中使用的化学、生物或免疫学成分、溶液或制剂。
IVD 试剂盒的试剂使用成本通常很高。尽管如此，已经出现了各种新的措施来解决这个问题，其中包括大量购买试剂和本地开发和生产检测系统。作为一个发达经济体，澳大利亚建立了本地免疫检测试剂计划，以生产低成本、高质量的免疫检测试剂。这些项目的工具包现在逐渐变得可用，并可能推动市场扩张。
To understand key trends, Download Sample Report
竞争格局
澳大利亚体外诊断市场竞争适度。该市场的一些主要参与者包括 BioMerieux、F. Hoffmann-La Roche Ltd、Becton、Dickinson and Company、Bio-Rad Laboratories Inc. 和 Abbott。主要参与者占据了大部分市场份额。随着技术的进步和产品的创新，一些小公司也纷纷进入研究市场，目前占有相当大的市场份额。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 High Prevalence of Chronic Diseases
-
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
-
4.2.3 Advanced Technologies
-
-
4.3 Market Restraints
-
4.3.1 Stringent Regulations
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Test Type
-
5.1.1 Clinical Chemistry
-
5.1.2 Molecular Diagnostics
-
5.1.3 Immuno Diagnostics
-
5.1.4 Haematology
-
5.1.5 Other Test Types
-
-
5.2 By Type of Product
-
5.2.1 Instruments
-
5.2.2 Reagents
-
5.2.3 Other Types of Product
-
-
5.3 By Application
-
5.3.1 Infectious Disease
-
5.3.2 Diabetes
-
5.3.3 Cancer/Oncology
-
5.3.4 Cardiology
-
5.3.5 Autoimmune Disease
-
5.3.6 Other Applications
-
-
5.4 By End User
-
5.4.1 Diagnostic Laboratories
-
5.4.2 Hospitals and Clinics
-
5.4.3 Other End Users
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 BioMerieux
-
6.1.2 F. Hoffmann-La Roche Ltd
-
6.1.3 Becton, Dickinson and Company
-
6.1.4 Bio-Rad Laboratories Inc.
-
6.1.5 Abbott
-
6.1.6 Siemens AG
-
6.1.7 Thermo Fisher Scientific
-
6.1.8 QIAGEN
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Australia In-vitro Diagnostics Market market is studied from 2018 - 2026.
What is the growth rate of Australia In-vitro Diagnostics Market?
The Australia In-vitro Diagnostics Market is growing at a CAGR of 5.36% over the next 5 years.
Who are the key players in Australia In-vitro Diagnostics Market?
bioMérieux SA, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Abbott are the major companies operating in Australia In-vitro Diagnostics Market.
